Andrew G Robinson
Overview
Explore the profile of Andrew G Robinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
6892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Nguyen P, Kain D, Robinson A, Kulkarni A, Johnson D, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244278.
PMID: 38587847
Importance: Patients with stage IV non-small cell lung cancer (NSCLC) experience substantial morbidity and mortality. Contact days (ie, the number of days with health care contact outside the home) measure...
2.
Owen D, Singh N, Ismaila N, Masters G, Riely G, Robinson A, et al.
J Clin Oncol
. 2023 Jul;
41(24):e63-e72.
PMID: 37433095
.
3.
Robinson A, Nguyen P, Goldie C, Jalink M, Hanna T
Front Oncol
. 2023 Apr;
13:1146053.
PMID: 37081984
Introduction: Population-based datasets are often used to estimate changes in utilization or outcomes of novel therapies. Inclusion or exclusion of unstaged patients may impact on interpretation of these studies. Methods:...
4.
Moffat G, Wang T, Robinson A
J Natl Compr Canc Netw
. 2023 Feb;
21(4):336-339.
PMID: 36791749
This report describes the management of small cell lung cancer (SCLC) transformation in a patient with untreated ALK-mutated advanced disease and a minimal smoking history, and a separate case of...
5.
Novello S, Kowalski D, Luft A, Gumus M, Vicente D, Mazieres J, et al.
J Clin Oncol
. 2023 Feb;
41(11):1999-2006.
PMID: 36735893
JCO We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435). Eligible patients with previously untreated, metastatic squamous non-small-cell lung cancer (NSCLC) were randomly...
6.
Owen D, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, et al.
J Clin Oncol
. 2022 Dec;
41(5):e10-e20.
PMID: 36534938
.
7.
Owen D, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, et al.
J Clin Oncol
. 2022 Dec;
41(5):e1-e9.
PMID: 36534935
.
8.
Singh N, Temin S, Baker Jr S, Blanchard E, Brahmer J, Celano P, et al.
J Clin Oncol
. 2022 Jul;
40(28):3323-3343.
PMID: 35816668
Purpose: To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer without driver alterations....
9.
Singh N, Temin S, Baker Jr S, Blanchard E, Brahmer J, Celano P, et al.
J Clin Oncol
. 2022 Jul;
40(28):3310-3322.
PMID: 35816666
Purpose: To provide evidence-based recommendations updating the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver...
10.
Robinson A, ODonnell J, Booth C, Koven R, Eisenhauer E, Brundage M
J Cancer Policy
. 2022 May;
30:100301.
PMID: 35559797
Background: Progression-free survival (PFS) is often used as a clinical trials outcome for evaluating new therapies for solid tumors. While PFS is a validated surrogate for overall survival (OS) or...